{"id":999824,"date":"2026-09-02T09:33:05","date_gmt":"2026-09-02T13:33:05","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/atrium-therapeutics-to-participate-in-upcoming-investor-conferences\/"},"modified":"2026-09-02T09:33:05","modified_gmt":"2026-09-02T13:33:05","slug":"atrium-therapeutics-to-participate-in-upcoming-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/atrium-therapeutics-to-participate-in-upcoming-investor-conferences\/","title":{"rendered":"Atrium Therapeutics to Participate in Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\">SAN DIEGO<\/span>, <span class=\"legendSpanClass\">Sept. 2, 2026<\/span> \/PRNewswire\/ &#8212; Atrium Therapeutics, Inc. (Nasdaq: RNA), a\u00a0biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted\u00a0to the heart, today announced that it will participate in upcoming investor conferences in September.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <img decoding=\"async\" src=\"https:\/\/mmx.prnewswire.com\/media\/MS1799411\/ATRIUM-Logo-RGB-Logo.jpg?id=OA2924566\" title=\"Atrium Therapeutics logo\" alt=\"Atrium Therapeutics logo\" \/>\n        <\/p>\n<\/p><\/div>\n<p>Since its launch earlier this year, Atrium has made meaningful progress including U.S. Food and Drug Administration (FDA) clearance of the Company&#8217;s Investigational New Drug (IND) application for ATR-1072 for the treatment of PRKAG2 syndrome, receipt of a No Objection Letter from Health Canada, the launch of the Corventis\u2122 Phase 1\/2 clinical trial, and the Company&#8217;s second quarter 2026 financial results reported in August.<\/p>\n<p>\n        <b>Conference Schedule:<\/b>\n      <\/p>\n<p>\n        <b>Wells Fargo 21<\/b><br \/>\n        <b><br \/>\n          <sup>st<\/sup><br \/>\n        <\/b><br \/>\n        <b> Annual Healthcare Conference<\/b>\n      <\/p>\n<ul type=\"disc\">\n<li>Fireside Chat on Tuesday, September 8 at 8:00 a.m. ET<\/li>\n<li>\n          <b>Date:<\/b>\u00a0September 8, 2026<\/li>\n<li>\n          <b>Location:<\/b>\u00a0Boston, MA<\/li>\n<\/ul>\n<p>\n        <b>2026 Cantor Global Healthcare Conference<\/b>\n      <\/p>\n<ul type=\"disc\">\n<li>Fireside Chat on Wednesday, September 9 at 11:30 a.m. ET<\/li>\n<li>\n          <b>Date:<\/b>\u00a0September 9, 2026<\/li>\n<li>\n          <b>Location:<\/b>\u00a0New York, NY<\/li>\n<\/ul>\n<p>\n        <b>Morgan Stanley 24<\/b><br \/>\n        <b><br \/>\n          <sup>th<\/sup><br \/>\n        <\/b><br \/>\n        <b> Annual Global Healthcare Conference<\/b>\n      <\/p>\n<ul type=\"disc\">\n<li>\n          <b>Date:<\/b>\u00a0September 16, 2026<\/li>\n<li>\n          <b>Location:<\/b>\u00a0New York, NY<\/li>\n<\/ul>\n<p>Details including webcast information will be available in the &#8220;<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4765464-1&amp;h=2247981326&amp;u=https%3A%2F%2Finvestors.atriumtherapeutics.com%2Fevents-and-presentations&amp;a=Events+and+Presentations\" target=\"_blank\" rel=\"nofollow\">Events and Presentations<\/a>&#8221; section of Atrium&#8217;s investor relations website at: <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4765464-1&amp;h=3947902041&amp;u=https%3A%2F%2Finvestors.atriumtherapeutics.com%2Fevents-and-presentations&amp;a=https%3A%2F%2Finvestors.atriumtherapeutics.com%2Fevents-and-presentations\" target=\"_blank\" rel=\"nofollow\">https:\/\/investors.atriumtherapeutics.com\/events-and-presentations<\/a>.<\/p>\n<p>A replay of the webcasts will be archived on Atrium&#8217;s website for at least 30 days following the presentations.<\/p>\n<p>\n        <b>About Atrium Therapeutics<\/b>\n      <\/p>\n<p>Atrium Therapeutics, Inc. (Nasdaq: RNA) is pioneering targeted delivery of ribonucleic acid (RNA) therapeutics to the heart to transform the standard of care for people living with cardiomyopathies. With the U.S. Food and Drug Administration&#8217;s (FDA) recent clearance of its Investigational New Drug (IND) application for ATR-1072 for PRKAG2 (Protein Kinase AMP-activated non-catalytic subunit Gamma 2) syndrome, Atrium is advancing its first precision cardiology program into the clinic through the Corventis Phase 1\/2 clinical trial. The Company&#8217;s proprietary technology &#8211; designed at Avidity Biosciences, Inc. &#8211; combines the tissue selectivity of monoclonal antibodies (mAbs) and other targeted delivery ligands with the precision of oligonucleotides, and is designed to selectively target the underlying drivers of genetically driven cardiac diseases through targeted, non-viral delivery of small interfering RNA (siRNA). This approach builds upon learnings from demonstrated delivery to skeletal muscle and applies it for efficient delivery to the heart, with the potential to overcome challenges associated with non-specific tissue delivery. Beyond ATR-1072, the Company&#8217;s pipeline includes ATR-1086 for PLN (phospholamban) cardiomyopathy and two undisclosed research targets in rare cardiomyopathies.<\/p>\n<p>For more information about our RNA delivery platform, development pipeline and people, please visit <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4765464-1&amp;h=2471088655&amp;u=https%3A%2F%2Fatriumtherapeutics.com%2F&amp;a=https%3A%2F%2Fatriumtherapeutics.com%2F\" target=\"_blank\" rel=\"nofollow\">https:\/\/atriumtherapeutics.com\/<\/a>\u00a0and engage with us on\u00a0<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4765464-1&amp;h=4277576806&amp;u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fatrium-therapeutics%2F&amp;a=LinkedIn\" target=\"_blank\" rel=\"nofollow\">LinkedIn<\/a>.<\/p>\n<p>\n        <b>Availability of Other Information About Atrium Therapeutics<\/b>\n      <\/p>\n<p>Investors and others should note that\u00a0Atrium Therapeutics\u00a0communicates with its investors and the public using its website\u00a0<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4765464-1&amp;h=2471088655&amp;u=https%3A%2F%2Fatriumtherapeutics.com%2F&amp;a=https%3A%2F%2Fatriumtherapeutics.com%2F\" target=\"_blank\" rel=\"nofollow\">https:\/\/atriumtherapeutics.com\/<\/a>, including, but not limited to,\u00a0Atrium Therapeutics&#8217;\u00a0disclosures, investor presentations and FAQs,\u00a0Securities and Exchange Commission\u00a0(SEC) filings, press releases, public conference call transcripts and webcast transcripts, as well as on LinkedIn. The information that\u00a0Atrium Therapeutics posts on its website or on LinkedIn could be deemed to be material information. As a result,\u00a0Atrium Therapeutics\u00a0encourages investors, the media and others interested to review the information that it posts there on a regular basis. The contents of\u00a0Atrium Therapeutics&#8217;\u00a0website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.<\/p>\n<p>\n        <b>Forward-Looking Statements<\/b>\n      <\/p>\n<p>This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding: Atrium&#8217;s planned participation at investor conferences; the availability of webcasts on Atrium&#8217;s website; the advancement of our clinical program for ATR 1072 for the treatment of PRKAG2 syndrome; the strength, versatility and therapeutic potential of Atrium&#8217;s RNA delivery platform; the potential therapeutic benefits of RNA-based therapies; and the potential advantages of our product candidates compared to alternative therapies for patients with cardiovascular diseases; and statements regarding our strategy, objectives, pipeline, and future operations. These statements are based on Atrium&#8217;s current plans, objectives, estimates, expectations and intentions, are not guarantees of future performance and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, but are not limited to, risks and uncertainties specified in Atrium&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 publicly filed by Atrium with the SEC and in other filings and furnishings made by Atrium with the SEC from time to time. Atrium is providing the information in this communication as of this date and does not undertake any obligation to update any forward-looking statements contained in this communication as a result of new information, future events or otherwise, except as required by law.<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=LA38781&amp;sd=2026-09-02\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/atrium-therapeutics-to-participate-in-upcoming-investor-conferences-302866964.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/atrium-therapeutics-to-participate-in-upcoming-investor-conferences-302866964.html<\/a><\/p>\n<p>SOURCE Atrium Therapeutics<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=LA38781&amp;Transmission_Id=202609020800PR_NEWS_USPR_____LA38781&amp;DateId=20260902\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire SAN DIEGO, Sept. 2, 2026 \/PRNewswire\/ &#8212; Atrium Therapeutics, Inc. (Nasdaq: RNA), a\u00a0biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted\u00a0to the heart, today announced that it will participate in upcoming investor conferences in September. Since its launch earlier this year, Atrium has made meaningful progress including U.S. Food and Drug Administration (FDA) clearance of the Company&#8217;s Investigational New Drug (IND) application for ATR-1072 for the treatment of PRKAG2 syndrome, receipt of a No Objection Letter from Health Canada, the launch of the Corventis\u2122 Phase 1\/2 clinical trial, and the Company&#8217;s second quarter 2026 financial results reported in August. Conference Schedule: Wells Fargo 21 st Annual Healthcare Conference Fireside Chat on Tuesday, September 8 at 8:00 a.m. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/atrium-therapeutics-to-participate-in-upcoming-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Atrium Therapeutics to Participate in Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-999824","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Atrium Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/atrium-therapeutics-to-participate-in-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Atrium Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire SAN DIEGO, Sept. 2, 2026 \/PRNewswire\/ &#8212; Atrium Therapeutics, Inc. (Nasdaq: RNA), a\u00a0biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted\u00a0to the heart, today announced that it will participate in upcoming investor conferences in September. Since its launch earlier this year, Atrium has made meaningful progress including U.S. Food and Drug Administration (FDA) clearance of the Company&#8217;s Investigational New Drug (IND) application for ATR-1072 for the treatment of PRKAG2 syndrome, receipt of a No Objection Letter from Health Canada, the launch of the Corventis\u2122 Phase 1\/2 clinical trial, and the Company&#8217;s second quarter 2026 financial results reported in August. Conference Schedule: Wells Fargo 21 st Annual Healthcare Conference Fireside Chat on Tuesday, September 8 at 8:00 a.m. &hellip; Continue reading &quot;Atrium Therapeutics to Participate in Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/atrium-therapeutics-to-participate-in-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-02T13:33:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mmx.prnewswire.com\/media\/MS1799411\/ATRIUM-Logo-RGB-Logo.jpg?id=OA2924566\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atrium-therapeutics-to-participate-in-upcoming-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atrium-therapeutics-to-participate-in-upcoming-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Atrium Therapeutics to Participate in Upcoming Investor Conferences\",\"datePublished\":\"2026-09-02T13:33:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atrium-therapeutics-to-participate-in-upcoming-investor-conferences\\\/\"},\"wordCount\":801,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atrium-therapeutics-to-participate-in-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS1799411\\\/ATRIUM-Logo-RGB-Logo.jpg?id=OA2924566\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atrium-therapeutics-to-participate-in-upcoming-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atrium-therapeutics-to-participate-in-upcoming-investor-conferences\\\/\",\"name\":\"Atrium Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atrium-therapeutics-to-participate-in-upcoming-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atrium-therapeutics-to-participate-in-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS1799411\\\/ATRIUM-Logo-RGB-Logo.jpg?id=OA2924566\",\"datePublished\":\"2026-09-02T13:33:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atrium-therapeutics-to-participate-in-upcoming-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atrium-therapeutics-to-participate-in-upcoming-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atrium-therapeutics-to-participate-in-upcoming-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS1799411\\\/ATRIUM-Logo-RGB-Logo.jpg?id=OA2924566\",\"contentUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS1799411\\\/ATRIUM-Logo-RGB-Logo.jpg?id=OA2924566\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atrium-therapeutics-to-participate-in-upcoming-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Atrium Therapeutics to Participate in Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Atrium Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/atrium-therapeutics-to-participate-in-upcoming-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Atrium Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk","og_description":"PR Newswire SAN DIEGO, Sept. 2, 2026 \/PRNewswire\/ &#8212; Atrium Therapeutics, Inc. (Nasdaq: RNA), a\u00a0biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted\u00a0to the heart, today announced that it will participate in upcoming investor conferences in September. Since its launch earlier this year, Atrium has made meaningful progress including U.S. Food and Drug Administration (FDA) clearance of the Company&#8217;s Investigational New Drug (IND) application for ATR-1072 for the treatment of PRKAG2 syndrome, receipt of a No Objection Letter from Health Canada, the launch of the Corventis\u2122 Phase 1\/2 clinical trial, and the Company&#8217;s second quarter 2026 financial results reported in August. Conference Schedule: Wells Fargo 21 st Annual Healthcare Conference Fireside Chat on Tuesday, September 8 at 8:00 a.m. &hellip; Continue reading \"Atrium Therapeutics to Participate in Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/atrium-therapeutics-to-participate-in-upcoming-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2026-09-02T13:33:05+00:00","og_image":[{"url":"https:\/\/mmx.prnewswire.com\/media\/MS1799411\/ATRIUM-Logo-RGB-Logo.jpg?id=OA2924566","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atrium-therapeutics-to-participate-in-upcoming-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atrium-therapeutics-to-participate-in-upcoming-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Atrium Therapeutics to Participate in Upcoming Investor Conferences","datePublished":"2026-09-02T13:33:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atrium-therapeutics-to-participate-in-upcoming-investor-conferences\/"},"wordCount":801,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atrium-therapeutics-to-participate-in-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/mmx.prnewswire.com\/media\/MS1799411\/ATRIUM-Logo-RGB-Logo.jpg?id=OA2924566","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atrium-therapeutics-to-participate-in-upcoming-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/atrium-therapeutics-to-participate-in-upcoming-investor-conferences\/","name":"Atrium Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atrium-therapeutics-to-participate-in-upcoming-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atrium-therapeutics-to-participate-in-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/mmx.prnewswire.com\/media\/MS1799411\/ATRIUM-Logo-RGB-Logo.jpg?id=OA2924566","datePublished":"2026-09-02T13:33:05+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atrium-therapeutics-to-participate-in-upcoming-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/atrium-therapeutics-to-participate-in-upcoming-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atrium-therapeutics-to-participate-in-upcoming-investor-conferences\/#primaryimage","url":"https:\/\/mmx.prnewswire.com\/media\/MS1799411\/ATRIUM-Logo-RGB-Logo.jpg?id=OA2924566","contentUrl":"https:\/\/mmx.prnewswire.com\/media\/MS1799411\/ATRIUM-Logo-RGB-Logo.jpg?id=OA2924566"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atrium-therapeutics-to-participate-in-upcoming-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Atrium Therapeutics to Participate in Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/999824","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=999824"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/999824\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=999824"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=999824"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=999824"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}